Executives from Travere Therapeutics (NASDAQ:TVTX) said the company is focused on advancing treatments in three rare diseases—IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), and homocystinuria (HCU)—as management discussed regulatory timelines, commercial momentum, and capital resources at Guggenheim’s Biotech Summit. Company overview: three rare disease priorities President and CEO Eric Dube said Travere is “focused exclusively […]